Home > Healthcare > Surgical Site Infection Control Market
Surgical Site Infection Control Market Size
Surgical Site Infection Control Market size will register significant growth between 2024 and 2032 due to rising guidance on exercising necessary cautions. With stringent regulations and recommendations aimed at reducing surgical site infections (SSIs), healthcare facilities are prioritizing infection control measures.
For instance, in May 2023, Updated recommendations for preventing surgical site infections advised discontinuing antibiotics immediately after closing the incision, as researchers found no evidence that postoperative antibiotic continuation reduces infection risk. Extended antibiotic use elevated the risk of C. difficile infection and antimicrobial resistance. Published in the journal Infection Control and Healthcare Epidemiology, "Strategies to Prevent Surgical Site Infections in Acute Care Hospitals" offers evidence-based strategies from top experts representing five medical organizations, spearheaded by the Society for Healthcare Epidemiology of America, for preventing infections across various surgeries.
The emphasis on proper sterilization techniques, use of antimicrobial coatings, and adherence to aseptic protocols drives demand for SSI control products and solutions. As healthcare providers strive to minimize the risk of SSIs, the market for surgical site infection control continues to grow in response to these evolving guidelines.
The surgical site infection control market is witnessing increased demand driven by ongoing research and developments focused on mitigating and reducing infections. As healthcare providers and researchers explore innovative approaches to combat surgical site infections (SSIs), there's a growing emphasis on finding effective strategies for prevention and treatment. Advancements in antimicrobial coatings, sterilization techniques, and wound care products contribute to the expansion of the market. The quest for novel solutions to enhance patient outcomes and reduce healthcare costs continues to drive demand for SSI control products and technologies. For instance, in February 2024, led by researchers from the University of Maryland School of Medicine, a significant multicenter clinical trial revealed that an iodine-containing antiseptic reduced post-surgical infections by approximately one-quarter in patients with limb fractures compared to another commonly used skin antiseptic.
The surgical site infection control market faces various restraints. Stringent regulatory requirements and compliance standards present challenges for product development and approval. Limited awareness among healthcare professionals about infection control measures may hinder market growth. Additionally, budget constraints in healthcare facilities may limit investment in advanced infection control technologies. Resistance to change and reluctance to adopt new practices could also impede market expansion. Overcoming these restraints requires concerted efforts in education, regulatory alignment, and technology innovation to ensure effective surgical site infection control measures.
Surgical Site Infection Control Market Trends
Rising advances in research studies and clinical trials conducted by leading companies are driving trends in the industry. With a focus on developing innovative solutions, these studies aim to enhance infection prevention strategies and reduce post-surgical complications. Through collaborative efforts and investment in cutting-edge technologies, companies are pioneering new approaches to mitigate surgical site infections. This trend underscores the industry's commitment to improving patient outcomes and optimizing healthcare practices, ultimately shaping the trajectory of the industry.
To cite an instance, in February 2024, PolyPid Ltd., a biopharmaceutical firm dedicated to enhancing surgical outcomes, reported significant advancements in its SHIELD II Phase 3 clinical trial by enrolling its 100th patient. This trial evaluated the effectiveness of D-PLEX100, a product candidate designed to prevent surgical site infections (SSIs) in abdominal colorectal surgeries. The SHIELD II trial's top-line results are anticipated in the latter half of 2024, with approximately 40 centers actively participating in the study.
Surgical Site Infection Control Market Analysis
Cesarean section will grow owing to increased maternal mortality rates and longer hospital stays. SSI has become a common complication for the dissatisfaction of patients and higher treatment costs. According to the WHO, cesarean section accounts for over 21% of all childbirths globally and could rise to 29% by 2030. A soaring number of preterm births, cultural norms, and quality of healthcare could play a pivotal role in boosting the preference for C-sections.
Hospitals will account for a considerable share of the market during the forecast period 2024-2032. An increased likelihood of hospital-acquired infection through bloodborne pathogen transmission will force companies to invest in the portfolio. Hospitals are likely to invest in efficient control systems, including disinfectants and surgical gloves. Considering that SSIs represent a significant economic and clinical burden on the healthcare system, leading companies are likely to prioritize control mechanisms.
North America surgical site infection control market share will expand on account of rising cases of deep incisional SSI and superficial incisional SSIs. The U.S. CDC has developed guidelines for the prevention of SSI amidst the increasing diabetic population, aging, and malnutrition. Recent developments are likely to play a pivotal role in mitigating the risk of SSIs across the region. Surgeons and healthcare providers emphasize the use of advanced technologies and protocols to prevent surgical site infections. This commitment to quality healthcare drives the demand for innovative infection prevention products and solutions, shaping the market landscape in North America.
Surgical Site Infection Control Market Share
Major companies operating in the surgical site infection control industry competitive landscape include:
- Johnson & Johnson
- 3M
- Belimed AG
- Becton
- Dickinson and Company
- Kimberly-Clark Corporation
- Getinge Group
- Steris Corporation
- Sotera Health
- bioMerieux SA
Surgical Site Infection Control Market News
In October 2023, Spartan Medical Inc., a company specializing in medical solutions and owned by veterans, initiated a campaign to raise awareness about Surgical Site Infections (SSIs) and mitigate their occurrence in medical facilities nationwide. Positioned at the forefront of the industry, Spartan Medical, Inc. is continuously tackling the issue of preventing SSIs through a dual approach. This strategy involved offering innovative sterile instruments and implants while providing top-notch wound care products.